Angiogenic targets for potential disorders

Fundamental and Clinical Pharmacology

Volumn 25, Issue 1, 2011, Pages 29-47

  Bhadada, Shraddha V ^a   Goyal, Bhoomika R ^a   Patel, Mayur M ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Angiogenesis; Angiogenic inducers; Angiogenic inhibitors; Angiostatin; Cancer; Cardiovascular disorders; Excessive angiogenesis; Insufficient angiogenesis; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOSTATIN; CANSTATIN; CHONDROMODULIN 1; DELTA LIKE LIGAND 4; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; INTERFERON; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PIGMENT EPITHELIUM DERIVED FACTOR; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTHRITIS; ATHEROSCLEROSIS; BONE DISEASE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; LIMB ISCHEMIA; MENORRHAGIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; ULCER HEALING; WOUND HEALING;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 78650934777     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00814.x     Document Type: Review

References (121)

1. Hirschi K.K., d'Amore P.A. Pericytes in the microvasculature. Cardiovasc. Res. (1996) 32 687-698.
2. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. (2001) 61 253-270.
3. Carmeliet P. Angiogenesis in health and disease. Nat. Med. (2003) 9 653-660.
4. Hyder S.M., Stancel G.M. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol. Endocrinol. (1999) 13 806-811.
5. Conway E.M., Collen D., Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res. (2001) 49 507-521.
6. Polverini P.J. The pathophysiology of angiogenesis. Crit. Rev. Oral Biol. Med. (1995) 6 230-247.
7. Prior B.M., Yang H.T., Terjung R.L. What makes vessels grow with exercise training? J. Appl. Physiol. (2004) 97 1119-1128.
8. Fava R.A., Olsen N.J., Spencer-Green G. et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. (1994) 180 341-346.
9. Koch A.E., ; Harlow L.A., Haines G.K. et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. (1994) 152 4149-4156.
10. Lee S.H., Wolf P.H., Escuredo R., Deutsch R., Jamieson S., Thistlethwaite P. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N. Engl. J. Med. (2000) 342 626-633.
11. Cooke J.P., Losordo D.W. Nitric oxide and angiogenesis. Circulation (2002) 105 2185-2191.
12. Gupta K., Zhang J. Angiogenesis: a curse or cure? Postgrad. Med. J. (2005) 81 236-242.
13. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. (1999) 189 300-308.
14. Post S., Peeters W., Busser E. et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J. Vasc. Res. (2008) 45 244-250.
15. Oike Y., Yasunaga K., Suda T. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. Int. J. Hematol. (2004) 80 21-28.
16. Morisada T., Kubota Y., Urano T., Suda T., Oike Y. Angiopoietins and angiopoietin-like proteins in angiogenesis. Endothelium (2006) 13 71-79.
17. Vallee B.L., Riordan J.F. Organogenesis and angiogenin. Cell. Mol. Life Sci. (1997) 53 803-815.
18. Moghaddam A., Zhang H.T., Fan T.P.D. et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl Acad. Sci. USA (1995) 92 998-1002.
19. Giatromanolaki A., Koukourakis M.I., Sivridis E. et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. (2001) 61 7992-7998.
20. Woods J.M., Mogollon A., Amin M.A., Martinez R.J., Koch A.E. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp. Mol. Pathol. (2003) 74 282-290.
21. Fosslien E. Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann. Clin. Lab. Sci. (2001) 31 325-348.
22. Curzio R., Oliver D., Agnese M. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Rev. Cancer (2004) 1654 51-67.
23. Blom I., van Dijk A., Wieten L. et al. In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury. Nephrol. Dial. Transplant. (2001) 16 1139-1148.
24. Stratton R., Shiwen X., Martini G. et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J. Clin. Invest. (2001) 108 241-250.
25. Chen C.C., Chen N., Lau L.F. The angiogenic factors Cyr61 and CTGF induce adhesive signaling in primary human skin fibroblasts. J. Biol. Chem. (2001) 276 10443-10452.
26. Shimo T., Kubota S., Kondo S. et al. Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett. (2001) 174 57-64.
27. Distler J.W., Hirth A., Kurowska-Stolarska M., Gay R.E., Gay S., Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q. J. Nucl. Med. (2003) 47 149-161.
28. Agrotis A., Kalinina N., Bobik A. Transforming growth factor-β, cell signaling and cardiovascular disorders. Curr. Vasc. Pharmacol. (2005) 3 55-61.
29. Frank J., Born K., Barker J.H., Marzi I. In vivo effect of tumor necrosis factor alpha on wound angiogenesis and epithelialization. Eur. J. Trauma (2003) 29 208-219.
30. Nabors L.B., Suswam E., Huang Y., Yang X., Johnson M.J., King P.H. Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells. Cancer Res. (2003) 63 4181-4187.
31. Gardiner T.A., Gibson D.S., de Gooyer T.E., de la Cruz V.F., McDonald D.M., Stitt A.W. Inhibition of tumor necrosis factor-α improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am. J. Pathol. (2005) 166 637-644.
32. Pucci A., Martino S., Celeste A. et al. Angiogenesis, tumor necrosis factor-α and procoagulant factors in coronary artery giant aneurysm of a fatal infantile Kawasaki disease. Cardiovasc. Pathol. (2008) 17 186-189.
33. Strieter R.M., Belperio J.A., Keane M.P. CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest (2002) 122 298S-301S.
34. Strieter R.M., Burdick M.D., Gomperts B.N., Belperio J.A., Keane M.P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. (2005) 16 593-609.
35. Salven P., Hattori K., Heissig B., Rafii S. Interleukin-1α promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J. (2002) 16 1471-1473.
36. Heidemann J., Ogawa H., Dwinell M.B. et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. (2003) 278 8508-8515.
37. McClintock J.Y., Wagner E.M. Role of IL-6 in systemic angiogenesis of the lung. J. Appl. Physiol. (2005) 99 861-866.
38. Rabascio C., Muratori E., Mancuso P. et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. (2004) 64 4373-4377.
39. Martin T.A., Watkins G., Lane J., Jiang W.G. Assessing microvessels and angiogenesis in human breast cancer, using VE cadherin. Histopathology (2005) 46 422-430.
40. Wang Y., Zhen Y., Shi Y. et al. Vitamin K epoxide reductase: a protein involved in angiogenesis. Mol. Cancer Res. (2005) 3 317-323.
41. Saito A., Sugawara A., Uruno A. et al. All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology (2007) 148 1412-1423.
42. Klagsbrun M., Moses M.A. Molecular angiogenesis. Chem. Biol. (1999) 6 217-224.
43. Folkman J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. (2003) 3 643-651.
44. Ying S., Jiah-si Z. Canstatin, a endogenous inhibitor of angiogenesis and tumor growth. Chin. J. Cancer Res. (2004) 16 229-234.
45. Lobov I.B., Renard R.A., Papadopoulos N. et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl Acad. Sci. USA (2007) 104 3219-3224.
46. Hayami T., Funaki H., Yaoeda K. et al. Expression of the cartilage derived anti-angiogenic factor chondromodulin-I decreases in the early stage of experimental osteoarthritis. J. Rheumatol. (2003) 10 2207-2217.
47. Sasisekharan R., Moses M.A., Nugent M.A., Cooney C.L., Langer R. Heparinase inhibits neovascularization. Proc. Natl Acad. Sci. USA (1994) 91 1524-1528.
48. Lee P.L.Q., Holme K.R., Symes J.F. Heparinase enhances collateral vessel development in the ischemic limb. Int. Surg. (2002) 87 260-268.
49. Ji W.R., Barrientos L.G., Llinas M. et al. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem. Biophys. Res. Commun. (1998) 247 414-419.
50. Zhou Y., Zheng Q., Gao J., Gu J. High level expression of kringle 5 fragment of plasminogen in Pichiapastoris. Biotechnol. Lett. (2005) 27 167-171.
51. Zhang L., Chen J., Ke Y., Mansel R.E., Jiang W.G. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int. J. Mol. Med. (2006) 17 937-944.
52. Filleur S., Volz K., Nelius T. et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res. (2005) 65 5144-5152.
53. Majewski S., Marczak M., Szmurlo A., Jablonska S., Bollag W. Retinoids, Interferon α, 1, 25-dihydroxyvitamin D3, their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RARα mediates the antiangiogenic effect of retinoids. Cancer Lett. (1995) 89 117-124.
54. Lachgar S., Charvéron M., Gall Y., Bonafé J.L. Inhibitory effects of retinoids on vascular endothelial growth factor production by cultured human skin keratinocytes. Dermatology (1999) 199 25-27.
55. Beatrice K.E., James B.H., Bozena A.A. et al. Troponin I peptide (Glu94-Leul23), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer. J. Gastrointest. Surg. (2003) 7 961-969.
56. Schwartz J.D., Sung M., Schwartz M. et al. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-α2a upon progression. Oncologist (2005) 10 718-727.
57. Lindner D.J. Interferons as antiangiogenic agents. Curr. Oncol. Rep. (2002) 4 510-514.
58. Volpert O.V., Fong T., Koch A.E. et al. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. (1998) 188 1039-1046.
59. Akhtar N., Padilla M.L., Dicjerson E.B. et al. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia (2004) 6 106-116.
60. Siddiqui F., Ehrhart E.J., Charles B. et al. Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. Int. J. Hyperthermia (2006) 22 587-606.
61. Harjai K.J., Chowdhury P., Grines C.L. Therapeutic angiogenesis: a fantastic new adventure. J. Interv. Cardiol. (2002) 15 223-229.
62. Rosingberg A., Khan T.A., Sellke F.W., Laham R.J. Therapeutic angiogenesis for myocardial ischemia. Expert Rev. Cardiovasc. Ther. (2004) 2 271-283.
63. Ye L., Haider H.K., Jiang S.J., Sim E.K. Therapeutic angiogenesis using vascular endothelial growth factor. Asian Cardiovasc. Thorac. Ann. (2004) 12 173-181.
64. Syed I.S., Sandborn T.A., Rosengart T.K. Therapeutic angiogenesis: a biologic bypass. Cardiology (2004) 101 131-143.
65. Friehs I., Moran A.M., Stamm C. et al. Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury. Ann. Thorac. Surg. (2004) 77 2004-2010.
66. Sica D.A. Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol. (2006) 24 1329-1331.
67. Sane D., Anton L., Brosnihan K. Angiogenic growth factors and hypertension. Angiogenesis (2004) 7 193-201.
68. Brizzi M.F., Formato L., Bonamini R. The molecular mechanisms of angiogenesis: a new approach to cardiovascular diseases. Ital. Heart. J. (2001) 2 81-92.
69. Khurana R., Simons M., Martin J.F., Zachary I.C. Role of angiogenesis in cardiovascular disease a critical appraisal. Circulation (2005) 112 1813-1824.
70. Collinson D.J., Donnelly R. Therapeutic angiogenesis in peripherial arterial disease: can biotechnology produce an effective collateral circulation? Eur. J. Vasc. Endovasc. Surg. (2004) 28 9-23.
71. Makinen K. Angiogenesis - a new goal in peripheral artery occlusive disease therapy. Acta Chir. Belg. (2003) 103 470-474.
72. Di Stefano R., Limbruno U., Barone D., Balbarini A. Therapeutic angiogenesis of critical lower limb ischemia. Review of the literature and prospects of research on stem cells. Ital. Heart. J. Suppl. (2004) 1(Suppl) 1-13.
73. Kok Ho T., Rajkumar V., Black D.C., Abrahan D., Baker D. Critical limb ischemia classification and therapeutic angiogenesis. Int. J. Angiol. (2005) 14 49-59.
74. Slevin M., Kumar P., Gaffney J., Kumar S., Jersy K. Can angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential. Clin. Sci. (2006) 111 171-183.
75. Tonnesen M.G., Feng X., Clark R.A. Angiogenesis in wound healing. J. Investig. Dermatol. Symp. Proc. (2000) 5 40-46.
76. Gunawan E., Tsuji S., Tsuji M. et al. Influences of Helicobacter pylori on gastric angiogenesis and ulcer healing in mice. J. Gastroenterol. Hepatol. (2002) 17 960-965.
77. Jenkinson L., Bardhan K.D., Atherton J., Kalia N. Helicobacter pylori prevents proliferative stage of angiogenesis in vitro: role of cytokines. Dig. Dis. Sci. (2002) 47 1857-1862.
78. Kim J.S., Kim J.M., Jung H.C., Song I.S. Helicobacter pylori down-regulates the receptors of vascular endothelial growth factor and angiopoietin in vascular endothelial cells: implications in the impairment of gastric ulcer healing. Dig. Dis. Sci. (2004) 49 778-786.
79. Hewett P., Nijjar S., Shams M., Morgan S., Gupta J., Ahmed A. Down-regulation of angiopoietin-1 expression in menorrhagia. Am. J. Pathol. (2002) 160 773-780.
80. Smith S. Angiogenesis, vascular endothelial growth factor and the endometrium. Hum. Reprod. Update (1998) 4 509-519.
81. Larger E. Hyperglycemia and angiogenesis. Med. Sci. (Paris) (2003) 19 840-846.
82. Hazarika S., Dokun A.O., Li Y., Popel A.S., Kontos C.D., Annex B.H. Impaired angiogenesis after hind limb ischemia in type 2 diabetes mellitus. differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ. Res. (2007) 101 948.
83. Simons M. Angiogenesis, arteriogenesis, and diabetes paradigm reassessed? J. Am. Coll. Cardiol. (2005) 46 835-837.
84. Martinez P., Esbrit P., Rodrigo A., Alvarez-Arroyo M.V., Martinez M.E. Age-related changes in parathyroid hormone-related protein and vascular endothelial growth factor in human osteoblastic cells. Osteoporos. Int. (2002) 13 874-881.
85. Liebow A.A. Pulmonary emphysema with special emphasis to vascular changes. Am. Rev. Respir. Dis. (1959) 80 67-93.
86. Kasahara Y., Tuder R.M., Taraseviciene-Stewart L. et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. (2000) 106 1311-1319.
87. Nadar S.K., Karalis L., Al Yemeni E., Blann A.D., Lip G.Y. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb. Haemost. (2005) 94 1071-1076.
88. Levine R.J., Maynard S.E., Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. (2004) 350 672-683.
89. Yano K., Brown L.F., Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J. Clin. Invest. (2001) 107 409-417.
90. Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthritis Res. (2002) 4(Suppl 3) S81-S90.
91. Szekanecz Z., Gáspár L., Koch A.E. Angiogenesis in rheumatoid arthritis. Front. Biosci. (2005) 10 1739-1753.
92. Drolet B.A., Esterly N.B., Frieden I.J. Hemangiomas in children. N. Engl. J. Med. (1999) 341 173-181.
93. Mueller B.U., Mulliken J.B. The infant with a vascular tumor. Semin. Perinatol. (1999) 23 332-340.
94. Powell J. Update on hemangiomas and vascular malformations. Curr. Opin. Pediatr. (1999) 11 457-463.
95. Takahashi K., Mulliken J.B., Kozakewich H.P., Rogers R.A., Folkman J., Ezekowitz R.A. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest. (1994) 93 2357-2364.
96. Nickoloff B.J. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J. Investig. Dermatol. Symp. Proc. (2000) 5 67-73.
97. Ng E.W.M., Adamis A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. (2005) 40 352-368.
98. Kang D.H., Joly A.H., Oh S.W. et al. Impaired angiogenesis in the remnant kidney model: I. potential role of vascular endothelial growth factor and thrombospondin-1. J. Am. Soc. Nephrol. (2001) 12 1434-1447.
99. Elsa B.R., Keith H., Srinivasan R. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int. (2001) 60 37-45.
100. Futrakul N., Butthep P., Laohareungpanya N., Chaisuriya P., Ratanabanangkoon K. A defective angiogenesis in chronic kidney disease. Ren. Fail. (2008) 30 215-217.
101. Pousa I.D., Mate J., Gisbert J.P. Angiogenesis in inflammatory bowel disease. Eur. J. Clin. Invest. (2008) 38 73-81.
102. Eichhorn M.E., Kleespies A., Angele M.K., Jauch K.W., Bruns C.J. Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch. Surg. (2007) 392 371-379.
103. Pang R.W.C., Poon R.T.P. Clinical implications of angiogenesis in cancers. Vasc. Health Risk Manag. (2006) 2 97-108.
104. Matsunaga T., Weihrauch D.W., Moniz M.C. et al. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation (2002) 105 2133.
105. Mignatti P., Rifkin D.B. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein (1996) 49 117-137.
106. Thurston G., Suri C., Smith K. et al. Leakage- resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 286 2511-2514.
107. Wiedlocha A. Following angiogenin during angiogenesis: a journey from the cell surface to the nucleolus. Arch. Immunol. Ther. Exp. (Warsz) (1999) 47 299-305.
108. Sengupta S., Sellers L.A., Matheson H.B., Fan T.P.D. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br. J. Pharmacol. (2003) 139 219-231.
109. Kireeva M.L., Latinkic B.V., Kolesnikova T.V. et al. Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp. Cell Res. (1997) 233 63-77.
110. Holmes A., Abraham D., Sa S., Shiwen X., Black C., Leask A. CTGF and SMADs, Maintenance of scleroderma phenotype is independent of SMAD signaling. J. Biol. Chem. (2001) 276 10594-10601.
111. Bertolino P., Deckers M., Lebrin F., Dijke P. Transforming growth factor β signal transduction in angiogenesis and vascular disorders. Chest (2005) 128 585S-590S.
112. Bussolino F., Wang J.M., Turrini F. et al. Stimulation of the Na+/H+ exchanger in human endothelial cells activated by granulocyte and granulocyte macrophage colony stimulating factor. Evidence for a role in proliferation and migration. J. Biol. Chem. (1989) 264 18284-18287.
113. Hockel M., Jung W., Vaupel P., Rabes H., Khaledpour C., Wissler J.H. Purified monocyte derived angiogenic substance (angiotropin) induces controlled angiogenesis associated with regulated tissue proliferation in rabbit skin. J. Clin. Invest. (1988) 82 1075-1090.
114. Oh J.S., Kucab J.E., Bushel P.R. et al. Insulin-like growth factor 1 inscribes a gene expression profile for angiogenic factor and cancer progression in breast epithelial cells. Neoplasia (2002) 4 204-217.
115. Matsumoto K., Nakamura T. Emerging multipotent aspects of hepaocyte growth factor. J. Biochem. (Tokyo) (1996) 119 591-600.
116. Ashley R.A., Dubuque S.H., Dvorak B., Woodward S.S., Williams S.K., Kling P.J. Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr. Res. (2002) 51 472-478.
117. Yasuda Y., Fujita Y., Masuda S. et al. Erythropoietin is involved in growth and angiogenesis in malignant tumors of female reproductive organs. Carcinogenesis (2002) 23 1797-1805.
118. Feldman E., Weinreich D., Carroll N. et al. Interferon γ-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann. Surg. Oncol. (2006) 13 125-133.
119. Boudier H.A. Arteriolar and capillary remodelling in hypertension. Drugs (1999) 58 37-40.
120. Roccaro A.M., Russo F., Cirulli T., Di Pietro G., Vacca A., Dammacco F. Antiangiogenesis for rheumatoid arthritis. Curr. Drug. Targets Inflamm. Allergy (2005) 4 27-30.
121. Leong T.T., Fearon U., Veale D.J. Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr. Rheumatol. Rep. (2005) 7 325-329.